India celebrates 1 billion vaccine doses
NEW DELHI – India celebrated giving its billionth COVID-19 vaccine dose on Thursday, a hopeful milestone for the South Asian country where the delta variant fueled a crushing surge earlier this year and missteps initially held back its inoculation campaign.
About half of India’s nearly 1.4 billion people have received at least one dose while around 20% are fully immunized, according to Our World in Data. Many of those shots have come in just the past couple of months, after the rollout languished in the first half of the year amid vaccine shortages and problems with the system for rolling them out.
The success of the campaign has been credited with driving down coronavirus cases since the devastating months at the start of the year when India was recording hundreds of thousands infections a day, hospitals buckled under the pressure, and crematoriums and graveyards became overwhelmed. But experts warn that India must speed up the delivery of second shots in order to ensure the outbreak doesn’t flare again.
The country widened the gap between shots from 12 to 16 weeks in order to administer more first doses at a time when supply was limited and infections were surging – a tactic countries like the
United Kingdom have used in times of crisis. But it created a lag in getting people fully immunized.
India is using vaccines that require two doses. Ramping up the second dose is “an important priority,” V.K. Paul, the head of the country’s COVID-19 taskforce, said last week.
“We would like to see this number go up. Complete coverage is absolutely critical,” Paul said.
For now, the country appears to have enough vaccines to do that – but its supplies will be watched closely since it is a major supplier of the shots globally.
The government is now optimistic that the country’s rising vaccine supply will be enough to cover its international and domestic commitments. Both of the two main suppliers have ramped up production, with the Serum Institute of India now producing around 220 million doses a month and Bharat Biotech about 30 million, Paul said.
Still, experts say the vaccine situation will need constant review. “There can be no written-in-stone rule – if infections rise drastically, they can again stop exports until there’s enough doses,” said K. Srinath Reddy, president of the Public Health Foundation of India.
On Thursday, India confirmed more than 18,400 new cases and 160 deaths – dramatically below the worst days in May when daily fatalities exceeded 4,000. Overall, the country has recorded around 34 million infections and over 450,000 deaths, according to the Health Ministry, though those figures, as elsewhere, are likely undercounts.
Even states where infections were swelling a few weeks ago, such as Kerala along the tropical Malabar coast, have seen a sustained decline.
“There is a sense of comfort that India has suffered the worst of the delta variant, but this must be accompanied with a feeling of caution,” said Reddy. “Even if cases go up, we are unlikely to see the scale of the surge earlier – if that does happen, it would be fairly unexpected.”